Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2016-06-17 Regulatory Filings
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG gibt exklusive Vertriebsvereinbarung mit FRATER-RAZES-Gruppe fur Algerien bekannt
Regulatory Filings Classification · 100% confidence The document is a press release dated June 17, 2016, announcing an exclusive distribution agreement between NanoRepro AG and FRATER-RAZES-Gruppe for Algeria. It details the products involved, the terms of the agreement (five years), and future sales plans. This type of announcement, which details a significant business development (a partnership/agreement) but is not a formal regulatory filing like a 10-K, earnings release (ER), or a change in management (MANG), fits best under the general category for corporate news or regulatory announcements that don't have a more specific code. Since it is a specific business agreement announcement, it is not a general Regulatory Filing (RNS) unless no other category fits. However, none of the provided codes explicitly cover 'Business Agreement' or 'Partnership Announcement'. Given the options, this is a specific corporate action announcement. It is not an Earnings Release (ER), Interim Report (IR), or a filing about capital structure (CAP) or management changes (MANG). It is a specific corporate news item. In the absence of a dedicated 'Business Development' or 'Partnership' code, and since it is a formal announcement distributed via DGAP (a service often used for regulatory news), the most appropriate fallback category for a specific, non-financial, non-governance corporate announcement is RNS (Regulatory Filings/General Regulatory Announcements). However, looking closely at the definitions, this is a specific corporate event announcement. If we must choose from the list, and recognizing that many such announcements are often classified broadly, RNS is the general catch-all. If the document were about a merger/takeover, it would be TAR. Since it is a distribution agreement, RNS is the best fit among the provided codes as a general corporate announcement not covered elsewhere.
2016-06-17 German
NanoRepro AG gibt den Abschluss einer Distributionsvereinbarung mit PHARMACIE CONSEIL fur sechs afrikanische Lander bekannt
M&A Activity Classification · 99% confidence The document is a press release dated June 15, 2016, announcing a new distribution agreement between NanoRepro AG and PHARMACIE CONSEIL for six African countries. It details the scope, duration, and expected impact of this commercial agreement. This type of announcement, focusing on a specific business development (a contract or partnership) rather than routine financial reporting (like 10-K, ER, or IR), fits best under the general category of regulatory news or corporate updates. Since there is no specific code for 'Distribution Agreement Announcement', and it is a formal corporate news item distributed via DGAP, it falls under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate announcements not covered by more specific codes like DIV, CAP, or MANG. It is not an Earnings Release (ER), Interim Report (IR), or a formal statutory filing like a 10-K.
2016-06-15 German
NanoRepro AG startet Zusammenarbeit mit global agierendem Pharmakonzern Glenmark in Sudafrika
M&A Activity Classification · 99% confidence The document is titled 'News Details' and begins with a date and a headline announcing a 'Zusammenarbeit' (collaboration) between NanoRepro AG and Glenmark. It uses terms like 'DGAP-News', 'Pressemitteilung' (Press Release), and discusses a new business agreement, product introduction, and initial order values. This structure strongly indicates a corporate announcement regarding business development, not a formal regulatory financial report (like 10-K, IR, or ER). Since it details a significant business event (a new partnership/distribution agreement), it is best classified as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general news releases that don't fit specific financial or governance categories, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Since it is a general news release about a business development, RNS serves as the best fit among the provided codes for non-standard, non-financial disclosures.
2016-05-25 German
NanoRepro AG: GBC Research veroffentlicht ausfuhrliches Research-Update und bestatigt Kaufempfehlung fur NanoRepro
Regulatory Filings Classification · 99% confidence The document is a press release announcing that GBC Research has published a detailed research update on NanoRepro AG and confirmed a 'Buy' recommendation. It details updated financial forecasts (revenue increase for 2016, fair value per share) based on the research firm's analysis. This content—an external research report summary and rating—does not fit the definitions for a formal regulatory filing (10-K, IR, ER), a management report (MDA), or a proxy statement (DEF 14A). It is a specific type of investor communication focused on external analysis and valuation, which aligns best with an Investor Presentation (IP) or, more broadly, a Regulatory Filing (RNS) if a more specific category is unavailable. However, since it is a detailed analysis and valuation update, 'Investor Presentation' (IP) is a strong candidate, although it is a summary of a research report rather than the company's own presentation. Given the context of external research being published, and the lack of a specific 'Research Report' code, this falls under general investor communication. Since it is a detailed analysis provided to the market, and not just a short announcement of a report's release (RPA), 'Investor Presentation' (IP) is the closest fit for detailed analytical content aimed at investors, even if it's third-party research being disseminated. If we strictly adhere to the definitions, it's an announcement about research, but the content is the research summary itself. Given the depth of financial figures and valuation, it is more substantial than a typical RNS. I will classify it as Investor Presentation (IP) as it serves the function of presenting investment rationale and valuation.
2016-05-23 German
NanoRepro AG gibt Kapitalerhohung mit Bezugsrecht und anschlieender Privatplatzierung aus Genehmigtem Kapital bekannt
Capital/Financing Update Classification · 99% confidence The document is a press release from NanoRepro AG dated May 10, 2016, announcing a capital increase ('Kapitalerhöhung') involving the issuance of new shares via a rights offering and subsequent private placement. Key terms like 'Kapitalerhöhung', 'Bezugsrecht', 'Privatplatzierung', and 'Emissionserlös' strongly indicate a financing activity. This aligns directly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific corporate action related to capital structure.
2016-05-10 German
Aufsichtsrat der NanoRepro AG verlangert Vorstandsvertrag mit Lisa Jungst
Board/Management Information Classification · 100% confidence The document is a press release ("Pressemitteilung") dated May 4, 2016, announcing that the Supervisory Board of NanoRepro AG extended the executive board contract of Lisa Jüngst for three years. This announcement concerns a change in senior management/board composition. Based on the definitions, this clearly falls under 'Board/Management Information' (MANG). The document is not an Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT).
2016-05-04 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.